CLDF Title
Home | Contact Us | Bookmark
 
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
 
HCV | Abstract Library
Abstract Library
 
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
 
 
          Abstract Details Back
 
 
     
 
Telaprevir to Boceprevir Switch Highlights Lack of Cross-Reactivity
  
 
 
Carlson A, Gregorich Z, Striker R. Clin Infect Dis. 2012 Dec 7. [Epub ahead of print]
  
     
 
Source

Department of Medicine, University of Wisconsin-Madison.

Abstract

Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.
 
 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare
providers only. Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.